Abbisko Therapeutics

We aspire to become a leading biopharmaceutical company to discover and develop novel and differentiated therapies in cancer and beyond
HKEx code：02256

[Abbisko Therapeutics @Abbisko2016]

2024 ESMO-GI | Abbisko presents new phase II clinical data of irpagratinib in combination with atezolizumab for advanced HCC. The presentation highlights that 220mg BID of irpagratinib in combination with atezolizumab demonstrated promising antitumor activity with an ORR of 50%.

[Abbisko Therapeutics @Abbisko2016]

Abbisko Therapeutics and Allist Pharmaceuticals Jointly
Announce the Initiation of a Phase 2 Clinical Study Evaluating oral PD-L1 small molecule ABSK043 in Combination with Furmonertinib Mesylate for the Treatment of Advanced Non-Small Cell Lung Cancer

[Abbisko Therapeutics @Abbisko2016]

25 April 2024, Abbisko Therapeutics announced that its innovative FGFR4 inhibitor, irpagratinib, has been granted Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA) for the treatment of Hepatocellular Carcinoma (HCC).

[Abbisko Therapeutics @Abbisko2016]

9 April 2024, Abbisko announced the completion of a total 94 patient enrollment for its pivotal Phase III trial, MANEUVER (ABSK021-301) STUDY , for evaluating the efficacy and safety of pimicotinib in patients with tenosynovial giant cell tumor (TGCT).

[Abbisko Therapeutics @Abbisko2016]

28 Feb. 2024, Abbisko presented the preliminary first-in-human results of its next-generation highly selective FGFR2/3 inhibitor ABSK061 in patients with advanced solid tumors during the 2024 European Society for Medical Oncology Targeted Anticancer Therapies Congress @myESMO.

[Abbisko Therapeutics @Abbisko2016]

23 Feb. 2023, Abbisko today announced the first patient dose has been completed with next-generation EGFR Exon20ins inhibitor ABSK112 for NSCLC. ABSK112 is a next-generation oral EGFR Exon20ins inhibitor with high potency, high selectivity, and strong brain penetrating ability.

[Abbisko Therapeutics @Abbisko2016]

@merckgroup Delegation Visited Abbisko Shanghai R&D Center

Recently, a delegation led by Mr. Peter Guenter, Member of the Executive Board and Chief Executive Officer of Healthcare at Merck Group, visited Abbisko's Shanghai R&D Center.

[Abbisko Therapeutics @Abbisko2016]

6 Feb. 2024, Shanghai—Abbisko Therapeutics Co., Ltd. (“Abbisko Therapeutics”) announced that it had received the upfront payment of US$70 million upon the entry into a licensing agreement for pimicotinib（ABSK021）with @merckgroup in December 2023.

[Abbisko Therapeutics @Abbisko2016]

9 January, 2024, Abbisko (HKEX code: 02256) announced that its investigational innovative CSF-1R inhibitor pimicotinib（ABSK021） has been granted orphan drug designation（ODD） by the European Medicines Agency (EMA) for the treatment of inoperable tenosynovial giant cell tumor

[Abbisko Therapeutics @Abbisko2016]

2024 ESMO TAT Oral Presentation

Presentation Number: 450
Title： First-in-human Study of ABSK061, A Selective Fibroblast Growth Factor Receptor FGFR2/3 Inhibitor for Treating Patients with Advanced Solid Tumors 
Lecture Time：16:37 - 16:45
Time：26 February 2024

[Abbisko Therapeutics @Abbisko2016]

Abbisko Completed the First Patient Dose in Phase I Clinical Trial for Novel Small Molecule CD73 Inhibitor ABSK051.
ABSK051 is a novel small molecule CD73 inhibitor with strong inhibition against CD73 enzymatic activity.

[Qiming Venture Partners @QimingVC]

Our portfolio companies @ZaiLab_Global, @QuantaSing, New Horizon Health, @Xiaomi, @Abbisko2016, Tuhu, Venus Medtech, Zhihu, @antengene, and @meituan won nearly 15 awards at the 8th Zhitongcaijing Listed Companies Annual Selection Ceremony. #QMPortfolio

[Abbisko Therapeutics @Abbisko2016]

14 Dec.2023, Abbisko today announced that its CSF-1R inhibitor pimicotinib（ABSK021）has been granted the fast track designation（FTD） by the U.S. FDA for the treatment of tenosynovial giant cell tumor (TGCT) patients that are not amenable to surgery.

[Abbisko Therapeutics @Abbisko2016]

Abbisko out-licenses pimicotinib to Merck KGaA in $605M deal
Link：https://t.co/12ZEEH8rlG

[Abbisko Therapeutics @Abbisko2016]

Abbisko Therapeutics announced that it has entered into a licensing agreement with Merck. Merck will be granted an exclusive license to commercialize products comprising or containing pimicotinib (ABSK021) for all indications in Chinese mainland, Hong Kong, Macau and Taiwan.

[Abbisko Therapeutics @Abbisko2016]

28 Nov. 2023, Abbisko announced the first patient has been dosed in the study titled “A Multicenter, Open-Label Phase II Study To Evaluate The Efficacy And Safety Of ABSK021 In Combination With Chemotherapy With Or Without Toripalimab In Patients With Advanced Pancreatic Cancer

[Abbisko Therapeutics @Abbisko2016]

9 Nov 2023, Shanghai—Abbisko Therapeutics today announced that ABSK051, a novel small molecule CD73 inhibitor, has obtained the clinical trial approval from the National Medical Products Administration (NMPA) of the People’s Republic of China.
#bio #pharma #inhibitor #cancer

[Abbisko Therapeutics @Abbisko2016]

Abbisko Therapeutics Obtained Approval from U.S. FDA to Conduct First-in-Human (FIH) Clinical Study of A Next-Generation FGFR4 Mutant Inhibitor ABSK012

[Abbisko Therapeutics @Abbisko2016]

3 November 2023, Abbisko announced that upon 1-year follow-up with pimicotinib treatment in TGCT patients compared to the 6-month data previously reported in CTOS of last year, with an ORR of 87.5% (28/32, including 3 CR) in the 50 mg QD cohort and 66.7% (8/12, including 2 CR).

[Abbisko Therapeutics @Abbisko2016]

Abbisko will present two clinical updates of Pimicotinib（ABSK021）at the 2023 Connective Tissue Oncology Society (CTOS) Annual Meeting

Abstract ID: 1572315
Abstract ID: 1571943